Abstract

Introduction
Cancer is the leading cause of death among Alaska Native people. The objective of this study was to examine cancer incidence data for 2007–2011, age-specific rates for a 15-year period, incidence trends for 1970–2011, and mortality trends for 1990–2011.

Methods
US data were from the Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat database and from the SEER Alaska Native Tumor Registry. Age-adjusted cancer incidence rates among Alaska Native people and US whites were compared using rate ratios. Trend analyses were performed using the Joinpoint Regression Program. Mortality data were from National Center for Health Statistics.

Results
During 2007–2011 the cancer incidence rate among Alaska Native women was 16% higher than the rate among US white women and was similar among Alaska Native men and US white men. Incidence rates among Alaska Native people exceeded rates among US whites for nasopharyngeal, stomach, colorectal, lung, and kidney cancer. A downward trend in colorectal cancer incidence among Alaska Native people occurred from 1999 to 2011. Significant declines in rates were not observed for other frequently diagnosed cancers or for all sites combined. Cancer mortality rates among Alaska Native people during 2 periods, 1990–2000 and 2001–2011, did not decline. Cancer mortality rates among Alaska Native people exceeded rates among US whites for all cancers combined; for cancers of the lung, stomach, pancreas, kidney, and cervix; and for colorectal cancer.

Conclusion
Increases in colorectal screening among Alaska Native people may be responsible for current declines in colorectal cancer incidence; however, improvements in treatment of colon and rectal cancers may also be contributing factors.

Introduction
Cancer is the leading cause of death among Alaska Native (AN) people (1). Before the mid-1900s, cancer was considered a rare disease among AN people, but since then, cancer incidence has increased dramatically (2). Reports of salivary and esophageal cancers in the 1960s showed emerging patterns of cancer among Eskimo people in Alaska (3–7). During that time, cancer mortality overall did not differ from mortality among US whites; however, significantly higher mortality was noted for cancer of the nasopharynx, salivary glands, kidney, esophagus, and cervix (8). Subsequent cancer surveillance efforts showed that overall incidence was below expected rates for 1969–1973 (based on Connecticut cancer incidence rates) but that incidence exceeded expected rates for cancer of the nasopharynx, liver, salivary gland, gallbladder, kidney, and thyroid. Significantly lower incidence rates among AN people compared with US whites were reported for melanoma, lymphoma, and leukemia (9). Since then, we reported emerging patterns in cancer incidence among AN people, such as declines in cervical cancer incidence and increases in lung, breast, and colorectal cancer (CRC) (10–13). Cancer incidence data emphasize the unique patterns of cancer among the AN population compared with other US populations and guide culturally relevant programs in cancer education, prevention, and control.
The term “Alaska Native” refers to 3 broadly defined groups of indigenous people living in Alaska: Eskimo, Indian, and Aleut. AN people comprise approximately 18% of the Alaskan population; 33% live in one of 2 major cities. Health care for AN people was the responsibility of the Indian Health Service (IHS) until 1997, when the Alaska Tribal Health Compact, a self-governance agreement, allowed tribal governments and their regional health corporations to assume this responsibility (14). The objective of this study was to examine cancer incidence and mortality data for AN people from 1970 through 2011.

Methods

US data are from the Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat database and from the SEER Alaska Native Tumor Registry, a population-based registry that includes AN people who lived in Alaska at the time of cancer diagnosis from 1969 to 2011 and who met eligibility requirements for IHS benefits (15). Tumor data and demographic information for AN patients were gathered from electronic medical records, medical charts, pathology reports, and provider dictations from the Alaska Native Medical Center and regional medical facilities. Cancers described in this report include only invasive cancers. Classification of site of cancer origin, histologic cell type, behavior, and grade coding followed the International Classification of Diseases for Oncology, second and third editions. Cancer sites of origin were grouped according to SEER site groups. Less than 1% of the cases were identified from death certificates only; 89% of cancers were histologically confirmed. Abstracting followed detailed coding and staging guidelines established by the SEER program, and data were processed through a standard set of computerized edits. SEER data quality is monitored through periodic record review and other SEER data quality-improvement activities. AN population estimates were obtained from the US Census (1970, 1980, and 1990) and from National Center for Health Statistics’ bridged population series for ANs (1981–2010), obtained from the SEER*Stat website (16). Cancer incidence rates were expressed as average annual rates per 100,000 population for a 5-year period, 2007–2011. Age-specific cancer incidence rates were based on data for 2000–2011. US cancer incidence data for 2000–2011 were obtained from a SEER*Stat data set based on 18 registries (17); US trend data for 1973–2011 were obtained from a SEER*Stat data set based on 13 registries (18). AN and US white mortality rates were calculated for years 2007–2011 using data from the National Center for Health Statistics, available from SEER*Stat (19). Incidence and mortality rates, rate ratios (RRs), and corresponding 95% confidence intervals were computed using SEER*Stat statistical software version 8.1.2 (20). Rates were age-adjusted to the US Census 2000 standard population using the direct method for comparison with US white incidence rates. Trend analysis of 2-year averaged incidence rates for 1970–2011 was performed using the Joinpoint Regression Program, version 4.0.4 (21). The Joinpoint regression models determined the best fit for a single line or multisegmented lines across 2-year averaged incidence rates among ANs and US whites. Annual percentage change (APC) in trends was noted for cancers showing significant changes in trend; probability level was set at P = .05.

We calculated 11-year average annual age-adjusted death rates for 2 periods: 1990–2000 and 2001–2011. Age-adjustments were performed using the direct method and the 2000 US Census data. Rates were compared and considered significantly different when there was no overlap of confidence intervals.

Results

Among Alaska men and women, 1,968 cases of invasive cancer were diagnosed during 2007–2011. The age-adjusted incidence rate among AN women for all cancer sites combined was 16% higher than the rate among US white women (RR = 1.16; P < .001); however, the rate among AN men was not significantly different from the rate among US white men (RR = 0.94; P = .11) (Table 1). The leading cancers among AN and US white populations were lung, colorectal, and prostate cancer among men, and breast, colorectal, and lung cancer among women. We found striking differences in incidence rates between ANs and US whites for several sites. Incidence rates for lung and CRC among ANs exceeded rates among US whites (lung: RR\textsubscript{men} = 1.59, P < .001; RR\textsubscript{women} = 1.44, P < .001; colorectal: RR\textsubscript{men} = 1.92, P < .001; RR\textsubscript{women} = 2.03, P < .001). The prostate cancer rate among AN men was significantly lower than the rate among US white men (RR = 0.48, P < .001). Whereas breast cancer rates among AN women were once lower than rates among US white women, we found similar rates (RR = 1.02, P = .66). Other disparities between ANs and US whites were observed. Significantly higher rates among ANs were found for the following sites: nasopharynx (RR\textsubscript{men} = 10.71, P < .001; RR\textsubscript{women} = 10.39, P < .001), stomach (RR\textsubscript{men} = 2.82, P < .001; RR\textsubscript{women} = 3.94, P < .001), and kidney (RR\textsubscript{men} = 1.39, P = .04; RR\textsubscript{women} = 1.90, P < .001). Significantly lower rates among ANs were found for melanoma of the skin (RR\textsubscript{men} = 0.09, P < .001; RR\textsubscript{women} = 0.14, P < .001), urinary bladder (RR\textsubscript{men} = 0.57, P = .002), thyroid (RR\textsubscript{women} = 0.68, P = .03), non-Hodgkin lymphoma (RR\textsubscript{men} = 0.52, P = .001), and leukemia (RR\textsubscript{men} = 0.43, P = .002; RR\textsubscript{women} = 0.53, P = .01).
Age-specific rates

Age-specific incidence rates for all cancer sites combined were similar among AN and US white men for most 10-year age groups (Table 2). AN women aged 50 to 79 had significantly higher rates than US white women of similar age, and AN men aged 50 to 69 had significantly lower rates than US white men of similar age. Stomach and CRC incidence rates, which are 2 or more times higher among ANs than among US whites, showed disparities across nearly all 10-year age groups. Disparities in lung cancer rates were greatest among the older age groups. Breast cancer rates among AN women were similar to rates among US white women for half of the 10-year age groups. Prostate cancer rates were much lower among AN men aged 50 to 79 than among US white men of similar age. Kidney cancer incidence among ANs by age group was generally similar to rates among US whites, but rates were higher among AN men aged 70 to 79 than US men of similar age and among AN women aged 50 to 59 than US white women of similar age.

Cancer time trends

Joinpoint analysis indicated a 1.1% annual increase in combined cancer incidence rates among AN men and women during 1970–2005 (Table 3). The annual rate of increase among AN women (1.2%) was greater than the rate among AN men (0.7%) during 1970–2011. All site rates among US white men increased 1.5% annually during 1973–1989 and decreased 0.5% annually during 1995–2011. Rates among US white women increased during 1973–1982 (0.5% annually) and 1985–1999 (0.5% annually); no significant declines were found.

Joinpoint analysis of incidence rates by cancer site groups indicated significant increases in rates among men and women of both races. Only lung cancer rates among US whites showed any significant declines. Significant increases of 1.6% annually in CRC incidence among AN men and women combined were found for 1970–1999. Significant annual declines of 2.6% in CRC incidence among AN men and women combined were found for 1999–2011 (Figure 1). Declines in CRC among AN men or women were not significant. Declines of 2% annually in rates of CRC among US white men and women were found for 1985–1995, 10 or more years earlier than the decline among ANs.

Breast cancer rates among AN women increased significantly by 5.1% annually during 1970–1997. No significant increases or decreases in breast cancer incidence rates among AN women were found for later years. Rates among US white women increased 3.8% annually during 1980–1987 and later declined by 0.8% annually during 1999–2011.

Cancer mortality rates

No change was found in the cancer mortality rate for all sites combined among AN people between the 2 periods examined (1990–2000 and 2001–2011). Mortality rates among AN people did not change over time for the leading cancers (lung, colorectal, and breast cancer) (Figure 2). However, mortality rates among US whites declined significantly by the second period for all cancer sites combined (lung, colorectal, breast, and prostate cancer). Lung cancer was the leading cause of cancer death for both periods and both races. Lung and CRC mortality rates among ANs were significantly higher than rates among US whites for both periods.
Patterns of cancer incidence and mortality are not similar among American Indian and AN (AI/AN) groups in the United States. Incidence rates for all cancer sites combined among AI/AN groups are lower than rates among US whites; however, AI/AN cancer rates by IHS region show striking differences between AI/AN groups and US whites. Underreporting of cancer incidence because of race misclassification was demonstrated in several studies that linked cancer registry and IHS registration data (23–26). Studies on cancer conducted among AI/AN living in US counties containing tribal lands (or areas adjacent to tribal lands), where contract health services are provided for AI/ANs and where rates of race misclassification are lower, showed higher rates of certain cancers among AI/ANs in some IHS regions compared with rates among non-Hispanic whites from the same counties (27–29). The contract health services delivery area (CHSDA) counties grouped by IHS region showed higher incidence rates of lung cancer in the regions of the Northern Plains and Alaska; higher incidence rates of CRC in the regions of the Northern Plains, Southern Plains and Alaska; higher incidence rates of kidney cancer in the regions of the Northern Plains, Southern Plains, Southwest, and Alaska; and higher incidence rates of stomach cancer in the regions of the Northern Plains, Southern Plains, Pacific Coast, Southwest, and Alaska among AI/ANs than among non-Hispanic whites from the same regions (30–32). These studies underscore the disparity between AI/ANs and US whites and demonstrate geographic differences in cancer incidence.

Lung cancer rates among ANs have not declined as they have among US whites (22). High rates of lung cancer are likely to continue until tobacco use declines significantly. Since 2001, the Alaska Behavioral Risk Factor Surveillance System (BRFSS) survey has consistently measured rates of 38% to 45% for current smokers among the AN population — nearly double the rate among Alaska whites (33). Youth Risk Behavior Surveillance (YRBS) surveys in 2007, 2009, and 2011 among high school students in Alaska indicated that one-fourth to one-third of AN students were current smokers. Far fewer non-Native Alaska students in Alaska reported they were current smokers (10%–13%) in the same surveys (34).

In 2003, Alaska Native Tribal Health Consortium (ANTHC) established a Tobacco Prevention and Control Program to build capacity for tribal health organizations of the Alaska Tribal Health System to develop, expand, or revitalize nicotine-dependence treatment services. Later, tobacco treatment specialists who received educational training on tobacco cessation became community-based resources for providing information on quitting tobacco and counseling to those who had decided to quit. Training of these specialists continues.
Cancer incidence and mortality among US men declined rapidly after 1998 and among women after the 1970s (37). We found a significant decrease of 2.6% annually in CRC incidence rates among AN men and women combined for 1999–2011. The recent decrease in incidence of CRC is probably due to a recent increase in colorectal screening efforts among AN people. Beginning in the early 1990s, when high incidence rates of CRC were documented, the ANTHC began endoscopy training for nurse practitioners and physician assistants, an effort to make colonoscopy more available (38). In 2007, ANTHC supported itinerant screening colonoscopy field clinics. ANTHC also began an outreach program to follow up and encourage colonoscopy for eligible members of families of patients diagnosed with CRC. This program added a patient navigator to encourage people due for colonoscopy to make a screening appointment. In addition, the patient navigators assisted people by scheduling precolonoscopy appointments, assisting with travel plans, sending out appointment reminders, and answering questions about the bowel preparation and procedure (39). As a result, the CRC screening rate among AN people 50 years or older increased from 29% in 2000 to 65% in 2011 (12). A grant awarded by the Centers for Disease Control and Prevention to individual Alaska tribal health organizations provides patient navigators in medical centers at several regional hubs to assist AN people in rural areas in accessing CRC screening. Because CRC screening has increased only during recent years, significant reductions in CRC mortality are not expected immediately.

National data indicate that breast cancer mortality has not declined among AI/AN women in the United States (40). Breast cancer incidence and mortality declines in US white women are attributed to decreases in the use of hormone replacement therapy, increases in screening by mammography, early detection of in situ disease, and improvements in breast cancer treatment. Breast cancer incidence rates were once low among AN women (13,41) but then increased dramatically from 1970 to 1997; they have since remained constant. Rates of mammography (mammography in the past 2 years) among AN women aged 50 to 74 who had a mammogram in the past 2 years (76.8%) are similar to rates among white women in Alaska (74.9%), according to BRFSS surveys for 2004–2012 (33). Thirty percent of AN women with breast cancer are diagnosed when they are younger than 50. Age-specific breast cancer incidence rates among AN women younger than 50 were 14% to 23% higher than rates among US white women in our analysis, although significantly different rates were found only among women aged 40 to 59. In light of these data, changing screening recommendations for mammography to an earlier age may be worthy of consideration. Further study is needed to understand how risk factors such as race, gravidity and parity, age at first mammogram, screening history, stage at diagnosis, use of hormone replacement therapy, and family history of breast cancer have influenced breast cancer incidence and mortality among AN women.

The US Healthy People 2020 target is to reduce death rates by 10% for all cancer deaths from 179 to 161 deaths per 100,000 people. The Healthy Alaskans 2020 target to reduce cancer death rates is 162 deaths per 100,000, an 8% reduction over the baseline rate of 176 per 100,000 (36). The AN cancer mortality rate for 2001–2011 was 246 per 100,000 for all cancer sites combined, 36% higher than the rate among US whites (181 per 100,000). A recent review indicated that cancer mortality among ANs has not changed, whereas rates among US whites declined in the past 2 decades (22). It is unlikely that AN people will meet the state or national 2020 targets of cancer mortality reduction, especially because smoking rates have not decreased.

CRC and breast cancer screening programs appear to be having an impact on controlling breast cancer incidence and reducing CRC incidence rates. It is not known how many people would benefit from increased screening efforts, but BRFSS data from survey years 2004–2012 combined indicated that approximately 23% of AN women aged 50 to 74 did not receive a mammogram in the 2 years before the telephone interview. BRFSS survey data from combined years 2010–2012 also indicated that 40% of AN men and women aged 50 or older have not had a sigmoidoscopy or colonoscopy.

The impact of the CRC screening program may contribute to future declines in CRC mortality rates. Improvements in treatment of cancer may also contribute to the relatively stable rates seen for breast and lung cancer. The impact of tobacco cessation programs is not detectable on tobacco use trends among AN adults according to BRFSS data. Further study is needed to examine changes in smoking behavior in regions where smoking cessation programs are most active.
Our study has several limitations. Classification of cancer cases by AI/AN race was largely determined by eligibility for tribal health services. Denominator data were obtained from the US Census; participants self-identified as a single race in census years 1970, 1980, and 1990. Beginning with the Census 2000, individuals could choose more than one race, and the combination of AI/AN plus another race inflated the expected population counts for AI/AN in Alaska by about 10%. Several adjustments were made to correct for the overestimate of the AN population, including the process of “bridging,” which allowed a comparison of data before and after the Census 2000. Although eligibility for tribal health services can be identified for cases, it cannot be determined from census data.

Many of our incidence and mortality counts had small values, and differences between rates were difficult to detect. Combining several years of data is often needed to provide reliable estimates, but shifts in trends may not be identified for several years when using this approach. Because of the small number of deaths, we could not perform Joinpoint analysis on AN mortality rates.

The objective of this study was to describe patterns in cancer incidence and mortality and trends over time among AN people, by age and sex, and to compare these data with US data to identify disparities. Our data provide information to assess the impact of cancer control interventions (such as colonoscopy in reducing CRC). Cancer incidence rates paired with risk factor data may provide communities with information from which cancer prevention programs may be built. We hope to provide a resource for health care providers, tribal leaders, communities, and individuals who work to improve the health of AN people.

Disparities in cancer persist among AN people. Overall cancer incidence rates for both sexes combined among AN people exceed rates among the US white population, largely because of a 16% excess rate among AN women. Rates among AN men and women are higher than rates among US whites for multiple site-specific cancers: lung, stomach, colorectal, kidney, and nasopharynx. Rates among ANs increased for all cancers and selected sites; whereas rates among US whites decreased — increasing cancer disparities. Further studies are needed to identify the causes for the unique cancer pattern and ways to enhance cancer control.

Acknowledgments

The authors recognize the work of the many cancer registrars and others working throughout the state who have ensured the completeness and accuracy of information on cancer among AN people. Funding for the SEER Alaska Native Tumor Registry is provided through Interagency Agreement No. Y1-PC-0064-01 with the National Institutes of Health, National Cancer Institute SEER Program.

Author Information

Corresponding Author: Janet J. Kelly, Alaska Native Tribal Health Consortium, Alaska Native Epidemiology Center, Division of Community Health Services, 3900 Ambassador Dr, Anchorage, Alaska 99508. Telephone: 907-729-3949. E-mail: jjkelly@anthc.org.

Author Affiliations: Anne P. Lanier, Teresa Schade, Jennifer Brantley; B. Michael Starkey, Alaska Native Tribal Health Consortium, Alaska Native Epidemiology Center, Division of Community Health Services, Anchorage, Alaska.

References

1. Day G, Holck P, Provost E. Alaska Native mortality update: 2004–2008. Anchorage: Alaska Native Epidemiology Center Report, Alaska Native Tribal Health Consortium; 2011. http://anthctoday.org/epicenter/publications/mortality/index.html. Accessed January 12, 2013.
2. Lanier AP, Kelly JJ, Maxwell J, McEvoy T, Homan C. Cancer in Alaska Native people, 1969–2003. Alaska Med 2006; 48(2):30–59.
3. Arthaud JB. Anaplastic parotid carcinoma (“malignant lymphoepithelial lesion”) in seven Alaska Natives. Am J Clin Pathol 1972;57(3):275–86.
4. Fortuine R. Characteristics of cancer in the Eskimos of southwestern Alaska. Cancer 1969;23(2):468–74.
5. Hurst EE. Malignant tumors in Alaska Eskimos, unique predominance of carcinoma of the esophagus in Alaska Eskimo women. Cancer 1964;17(9):1187–96.
6. Johnson MW, editor. Lung cancer among the Alaska Natives. Science in Alaska, Proceedings of the fifteenth Alaskan Science Conference. 1964Aug 31–Sep 4; Juneau, Alaska.
7. Torrey EF. Malignant neoplasms among Alaskan Natives: an epidemiologic approach to cancer. McGill Med J 1962; 31:107–15.
8. Blot WJ, Lanier AP, Fraumeni JFJr, Bender TR. Cancer mortality among Alaskan natives, 1960–69. J Natl Cancer Inst 1975;55(3):547–54.
9. Lanier AP, Bender TR, Blot WJ, Fraumeni JFJr, Hurlbert WB. Cancer incidence in Alaska natives. Int J Cancer 1976;18(4):409–12.
10. Lanier AP, Knutson LR. Cancer in Alaskan natives: a 15-year summary. Alaska Med 1986;28(2):37–41.
11. Lanier AP, Kelly JJ, Smith B, Harpster AP, Tanttila H, Amadon C, et al. Alaska Native cancer update: incidence rates 1989–1993. Cancer Epidemiol Biomarkers Prev 1996;5(9):749–51.
12. Lanier AP, Kelly JJ, Holck P, Smith B, McEvoy T, Sandige J. Cancer incidence in Alaska Natives thirty-year report 1969–1998. Alaska Med 2001;43(4):87–115.
13. Lanier AP, Kelly JJ, Maxwell J, McEvoy T, Homan C. Cancer in Alaska Native people, 1969-2003. Alaska Med 2006;48(2):30–59.
14. About the Alaska Native Tribal Health Consortium. Anchorage (AK): Alaska Native Tribal Health Consortium. http://anhtctoday.org/about/index.html. Accessed October 20, 2014.
15. Surveillance, Epidemiology and End Results program. Bethesda (MD): National Cancer Institute. http://seer.cancer.gov/about/. Accessed May 13, 2014.
16. Surveillance Epidemiology and End Results (SEER) program SEER*Stat database: Populations — total U.S. (1981–2011), state-level, by expanded race <single ages to 85+; Katrina/Rita adjustment>. Bethesda (MD): National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; released October 2012. http://www.seer.cancer.gov. Accessed May 13, 2014.
17. Surveillance Epidemiology and End Results (SEER) program SEER*Stat database: Incidence — SEER 18 regs research data + Hurricane Katrina impacted Louisiana cases, Nov 2013 sub (2000–2011) <Katrina/Rita population adjustment> linked to county attributes — total U.S., 1969–2012 counties. Bethesda (MD): National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; released April 2014, based on the November 2013 submission. http://www.seer.cancer.gov. Accessed May 13, 2014.
18. Surveillance Epidemiology and End Results (SEER) program SEER*Stat database: Incidence — SEER 9 regs research data, Nov 2013 sub (1973–2011) <Katrina/Rita population adjustment> linked to county attributes — total U.S., 1969–2012 counties. Bethesda (MD): National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; released April 2014, based on the November 2013 submission. http://www.seer.cancer.gov. Accessed May 13, 2014.
19. Surveillance Epidemiology and End Results (SEER) program SEER*Stat database: Mortality — all COD, aggregated with state, total U.S. (1990–2011) <Katrina/Rita population adjustment>. Bethesda (MD): National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; released July 2014. http://www.seer.cancer.gov. Underlying mortality data provided by National Center for Health Statistics. http://www.cdc.gov/nchs. Accessed September 26, 2014.
20. SEER*Stat statistical software, version 8.1.2. Bethesda (MD): National Cancer Institute, Surveillance Research Program, Surveillance Systems Branch. http://www.seer.cancer.gov/seerstat. Accessed May 13, 2014.
21. Joinpoint regression program, version 4.0.4. Bethesda (MD): National Cancer Institute; May 2013. http://surveillance.cancer.gov/joinpoint. Accessed July 28, 2014.
22. Edwards BK, Noone A-M, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual report to the nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014;120(9):1290–314.
23. Sugarman JR, Holliday M, Ross A, Castoria J, Hui Y. Improving American Indian cancer data in the Washington State Cancer Registry using linkages with the Indian Health Service and tribal records. Cancer 1996;78(7, Suppl):1564–8.
24. Partin MR, Rith-Najarian SJ, Slater JS, Korn JE, Cobb N, Soler JT. Improving cancer incidence estimates for American Indians in Minnesota. Am J Public Health 1999;89(11):1673–7.
25. Kwong S, Perkings C, Snipes K, Wright W. Improving American Indian cancer data in the California Cancer Registry by linkage with the Indian Health Service. J Registry Manag 1998;25:17–20.
26. Becker TM, Bettles J, Lapidus J, Campo J, Johnson CJ, Shipley D, et al. Improving cancer incidence estimates for American Indians and Alaska Natives in the Pacific Northwest. Am J Public Health 2002;92(9):1469–71.
27. Espey DK, Wiggins CL, Jim MA, Miller BA, Johnson CJ, Becker TM. Methods for improving cancer surveillance data in American Indian and Alaska Native populations. Cancer 2008; 113(5 Suppl):1120–30.

28. Wiggins CL, Espey DK, Wingo PA, Kaur JS, Wilson RT, Swan J, et al. Cancer among American Indians and Alaska Natives in the United States, 1999–2004. Cancer 2008;113(5 Suppl):1142–52.

29. Cobb N, Wingo PA, Edwards BK. Introduction to the supplement on cancer in the American Indian and Alaska Native populations in the United States. Cancer 2008;113(5 Suppl):1113–6.

30. Bliss A, Cobb N, Solomon T, Cravatt K, Jim MA, Marshall L, et al. Lung cancer incidence among American Indians and Alaska Natives in the United States, 1999–2004. Cancer 2008;113(5 Suppl):1168–78.

31. Perdue DG, Perkins C, Jackson-Thompson J, Coughlin SS, Ahmed F, Havercamp DS, et al. Regional differences in colorectal cancer incidence, stage, and subsite among American Indians and Alaska Natives, 1999–2004. Cancer 2008;113(5 Suppl):1179–90.

32. Wingo PA, King J, Swan J, Coughlin SS, Kaur J, Erb-Alvarez JA, et al. Breast cancer incidence among American Indian and Alaska Native women: US, 1999–2004. Cancer 2008;113(5 Suppl):1191–202.

33. Health risks in Alaska among adults — Alaska Behavioral Risk Factor Survey reports, 1990–2010. Anchorage (AK): State of Alaska, Department of Health and Social Services, Division of Public Health, Chronic Disease Prevention and Health Promotion. http://www.hss.state.ak.us/dph/chronic/hsl/brfss/publications.htm. Accessed July 7, 2014.

34. Youth Risk Behavior Survey (YRBS), 2003–2011. Anchorage (AK): State of Alaska, Department of Health and Social Services, Division of Public Health. http://dhss.alaska.gov/dph/Chronic/Pages/yrbs/yrbs.aspx. Accessed August 27, 2014.

35. Healthy people 2020: tobacco use. Washington (DC): US Department of Health and Human Services. www.HealthyPeople.gov/2020/topicsObjectives2020/overview.aspx?topicid=41. Accessed August 27, 2014.

36. Healthy Alaskans 2020. Anchorage (AK): State of Alaska, Department of Health and Social Services; 2013. http://hss.state.ak.us/ha2020/. Accessed August 27, 2014.

37. Edwards BK, Kohler BA, Ehemann C, Zauber AG, Anderson RN, Jemal A, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116(3):544–73.

38. Redwood D, Joseph DA, Christensen C, Provost E, Peterson VL, Espey D, et al. Development of a flexible sigmoidoscopy training program for rural nurse practitioners and physician assistants to increase colorectal cancer screening among Alaska Native people. J Health Care Poor Underserved 2009;20(4):1041–8.

39. Redwood D, Provost E, Perdue DG, Havercamp D, Espey D. The last frontier: innovative efforts to reduce colorectal cancer disparities among the remote Alaska Native population. Gastrointest Endosc 2012;75(3):474–80.

40. White A, Richardson LC, Li C, Ekwueme DU, Kaur JS. Breast cancer mortality among American Indian and Alaska Native women, 1990–2009. Am J Public Health 2014;104(Suppl 3):S432–8.

41. Kelly JJ, Lanier AP. Cancer in Alaska Native people, 1969–2008: 40-year report. Anchorage (AK): Alaska Native Tumor Registry, Epidemiology Center, Alaska Native Tribal Health Consortium; 2012. http://anthcoday.org/epicenter/publications/index.html. Accessed January 12, 2013.
### Table 1. Average Annual Age-Adjusted Cancer Incidence Rates\(^a\) per 100,000, Alaska Native and US White Men and Women, 2007–2011

| Cancer Site\(^b\)          | Men          | Women        | Rate Ratio (P Value) | Men          | Women        | Rate Ratio (P Value) |
|---------------------------|--------------|--------------|----------------------|--------------|--------------|----------------------|
|                           | No. Alaska Native | US White | Rate Ratio (P Value) | No. Alaska Native | US White | Rate Ratio (P Value) |
| All sites                 | 899          | 501.3       | 532.1                | 909          | 496.0       | 424.4                |
| Oral cavity and pharynx   | 39           | 18.5        | 17.0                 | 18           | 7.8         | 6.4                  |
| Nasopharynx               | 13           | 6.5         | 0.6                  | 6            | 2.7         | 0.3                  |
| Digestive system          | 310          | 167.2       | 99.9                 | 265          | 129.7       | 66.6                 |
| Esophagus                 | 9            | 4.1         | 8.0                  | 10           | 4.4         | 1.7                  |
| Stomach                   | 47           | 26.0        | 9.2                  | 38           | 17.6        | 4.5                  |
| Colon and rectum          | 173          | 95.6        | 49.6                 | 153          | 75.9        | 37.3                 |
| Colon only                | 109          | 64.8        | 34.3                 | 115          | 58.1        | 27.5                 |
| Rectum only               | 45           | 21.1        | 11.5                 | 30           | 14.1        | 7.1                  |
| Liver                     | 28           | 13.8        | 10.0                 | 12           | 5.8         | 2.9                  |
| Gallbladder               | 3            | 2.0         | 0.8                  | 6            | 3.6         | 1.4                  |
| Pancreas                  | 37           | 19.1        | 14.0                 | 28           | 14.1        | 10.7                 |
| Respiratory system        | 197          | 123.4       | 79.6                 | 152          | 79.0        | 55.7                 |
| Larynx                    | 12           | 7.0         | 6.0                  | 3            | 1.2         | 1.3                  |
| Lung and bronchus         | 183          | 115.3       | 72.4                 | 148          | 77.6        | 53.8                 |
| Bones and joints          | 3            | 0.9         | 1.2                  | 1            | 0.3         | 0.8                  |
| Soft tissue and heart     | 5            | 2.8         | 4.2                  | 11           | 4.2         | 2.8                  |
| Skin, excluding basal and squamous | 8  | 3.4        | 35.3                | 9            | 4.3         | 21.4                |
| Melanoma of the skin      | 7            | 3.1         | 32.3                 | 6            | 2.8         | 20.0                 |
| Breast                    | 1            | 0.7         | 1.2                  | 303          | 131.6       | 128.0                |
| Female genital system     | –            | –           | –                    | 113          | 47.5        | 50.5                 |
| Cervix uteri              | –            | –           | –                    | 30           | 11.2        | 7.8                  |
| Corpus uteri              | –            | –           | –                    | 41           | 16.6        | 25.4                 |
| Ovary                     | –            | –           | –                    | 28           | 13.4        | 13.0                 |
| Male genital system       | 140          | 76.6        | 147.7                | –            | –           | –                    |
| Prostate                  | 119          | 67.5        | 139.9                | –            | –           | –                    |
| Testis                    | 18           | 7.2         | 6.6                  | –            | –           | –                    |
| Urinary system            | 89           | 52.8        | 62.5                 | 53           | 26.2        | 21.0                 |
| Urinary bladder           | 34           | 22.5        | 39.4                 | 9            | 5.2         | 9.5                  |
| Kidney and renal pelvis   | 55           | 30.3        | 21.7                 | 44           | 21.0        | 11.0                 |

\(^a\) Source of data: Surveillance Epidemiology and End Results (SEER) program SEER*Stat database (17).

\(^b\) Not all cancer site subgroups are shown for the major cancer site groups.

---

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
Table 1. Average Annual Age-Adjusted Cancer Incidence Rates* per 100,000, Alaska Native and US White Men and Women, 2007–2011

| Cancer Site        | No. | Alaska Native | US White | Rate Ratio (P Value) | No. | Alaska Native | US White | Rate Ratio (P Value) |
|--------------------|-----|---------------|----------|----------------------|-----|---------------|----------|----------------------|
| Eye and orbit      | 3   | 2.2           | 1.1      | 2.07 (0.42)          | 0   | —             | —        | —                   |
| Brain and nervous system | 11  | 4.7           | 8.4      | 0.55 (.08)           | 19  | 7.0           | 6.0      | 1.17 (.56)          |
| Endocrine system   | 12  | 5.4           | 7.7      | 0.70 (.31)           | 38  | 15.2          | 21.1     | 0.72 (.05)          |
| Thyroid            | 11  | 5.2           | 6.9      | 0.75 (.45)           | 35  | 14.0          | 20.4     | 0.68 (.03)          |
| Lymphoma           | 30  | 13.8          | 28.2     | 0.48 (<.001)         | 31  | 14.2          | 19.8     | 0.71 (.08)          |
| Non-Hodgkin lymphoma | 27  | 13.1          | 24.9     | 0.52 (.001)          | 30  | 13.8          | 17.2     | 0.80 (.27)          |
| Myeloma            | 8   | 5.2           | 7.2      | 0.71 (.43)           | 5   | 2.2           | 4.3      | 0.50 (.15)          |
| Leukemia           | 18  | 7.7           | 17.5     | 0.43 (.002)          | 17  | 5.8           | 10.7     | 0.53 (.01)          |
| Mesothelioma       | 1   | 0.3           | 2.1      | 0.16 (.004)          | 0   | —             | —        | —                   |
| Kaposi sarcoma     | 2   | 1.3           | 0.9      | 1.51 (.81)           | 1   | 0.6           | 0.1      | 7.54 (.25)          |
| Undefined          | 22  | 14.5          | 10.5     | 1.37 (.25)           | 33  | 19.8          | 7.9      | 2.51 (<.001)        |

* Source of data: Surveillance Epidemiology and End Results (SEER) program SEER*Stat database (17).

b Not all cancer site subgroups are shown for the major cancer site groups.
### Table 2. Age-Specific Cancer Incidence Rates\(^a\) per 100,000 Population, Alaska Native and US White Men and Women, 2000–2011

| Cancer Site/Age Group, y | No. | Alaska Native Rate | US White Rate | Rate Ratio (P Value) | No. | Alaska Native Rate | US White Rate | Rate Ratio (P value) |
|-------------------------|-----|--------------------|---------------|---------------------|-----|--------------------|---------------|---------------------|
|                         |     |                    |               |                     |     |                    |               |                     |
| All sites               |     |                    |               |                     |     |                    |               |                     |
| 30–39                   | 84  | 98.4               | 81.6          | 1.20 (.11)          | 135 | 159.2              | 147.2         | 1.08 (.39)          |
| 40–49                   | 195 | 214.6              | 211.8         | 1.01 (.88)          | 358 | 392.4              | 355.7         | 1.10 (.07)          |
| 50–59                   | 424 | 646.4              | 712.6         | 0.90 (.04)          | 550 | 818.4              | 684.0         | 1.19 (<.001)        |
| 60–69                   | 535 | 1,556.8            | 1,841.0       | 0.84 (.01)          | 552 | 1,519.3            | 1,234.4       | 1.23 (<.001)        |
| 70–79                   | 485 | 2,827.2            | 2,938.4       | 0.96 (.11)          | 470 | 2,272.4            | 1,788.4       | 1.27 (<.001)        |
| ≥80                     | 188 | 3,217.2            | 3,212.3       | 1.00 (>.99)         | 209 | 2,210.8            | 1,978.5       | 1.11 (.12)          |
| Stomach                 |     |                    |               |                     |     |                    |               |                     |
| 30–39                   | 5   | 5.8                | 1.4           | 4.08 (.02)          | 11  | 13.2               | 12            | 11.13 (<.001)       |
| 40–49                   | 20  | 21.8               | 4.1           | 5.30 (<.001)        | 11  | 11.9               | 2.7           | 4.44 (<.001)        |
| 50–59                   | 23  | 35.1               | 11.2          | 3.14 (<.001)        | 11  | 16.4               | 5.3           | 3.07 (<.001)        |
| 60–69                   | 22  | 67.0               | 28.1          | 2.38 (<.001)        | 20  | 55.0               | 11.2          | 4.89 (<.001)        |
| 70–79                   | 25  | 151.0              | 51.3          | 2.94 (<.001)        | 18  | 87.9               | 22.6          | 3.89 (<.001)        |
| ≥80                     | 12  | 222.4              | 72.2          | 3.08 (<.001)        | 4   | 42.0               | 36.4          | 1.15 (.91)          |
| Colon and rectum        |     |                    |               |                     |     |                    |               |                     |
| 30–39                   | 13  | 15.2               | 6.7           | 2.25 (.01)          | 8   | 9.3                | 6.0           | 1.55 (.30)          |
| 40–49                   | 35  | 38.5               | 22.9          | 1.67 (.01)          | 52  | 57.0               | 19.7          | 2.89 (<.001)        |
| 50–59                   | 78  | 118.9              | 71.6          | 1.66 (<.001)        | 79  | 117.5              | 51.5          | 2.28 (<.001)        |
| 60–69                   | 106 | 303.5              | 160.4         | 1.89 (<.001)        | 87  | 241.0              | 106.7         | 2.25 (<.001)        |
| 70–79                   | 93  | 540.4              | 293.9         | 1.83 (<.001)        | 109 | 528.3              | 209.2         | 2.52 (<.001)        |
| ≥80                     | 35  | 611.1              | 402.4         | 1.51 (.03)          | 47  | 497.7              | 323.2         | 1.54 (.01)          |
| Lung                    |     |                    |               |                     |     |                    |               |                     |
| 30–39                   | 3   | 3.5                | 2.2           | 1.60 (.58)          | 1   | 1.1                | 2.5           | 0.43 (.70)          |
| 40–49                   | 20  | 21.7               | 16.8          | 1.29 (.31)          | 20  | 21.5               | 17.0          | 1.26 (.35)          |
| 50–59                   | 83  | 126.4              | 78.1          | 1.61 (<.001)        | 53  | 78.9               | 63.6          | 1.23 (.14)          |
| 60–69                   | 114 | 328.8              | 262.2         | 1.25 (.02)          | 102 | 283.4              | 197.3         | 1.43 (<.001)        |
| 70–79                   | 143 | 827.3              | 505.8         | 1.63 (<.001)        | 119 | 577.1              | 344.5         | 1.67 (<.001)        |
| ≥80                     | 46  | 785.8              | 524.9         | 1.49 (.01)          | 42  | 446.7              | 300.0         | 1.48 (.02)          |
| Breast                  |     |                    |               |                     |     |                    |               |                     |
| 30–39                   | —   | —                  | —             | —                   | 48  | 57.2               | 43.8          | 1.30 (.09)          |
| 40–49                   | —   | —                  | —             | —                   | 166 | 182.5              | 154.4         | 1.18 (.04)          |
| 50–59                   | —   | —                  | —             | —                   | 203 | 302.1              | 260.7         | 1.15 (.04)          |
| 60–69                   | —   | —                  | —             | —                   | 162 | 444.7              | 398.1         | 1.11 (.18)          |

\(^a\) Source of data: Surveillance Epidemiology and End Results (SEER) program SEER*Stat database (17).

(continued on next page)
Table 2. Age-Specific Cancer Incidence Rates per 100,000 Population, Alaska Native and US White Men and Women, 2000–2011

| Cancer Site/Age Group, y | Men | | | Women | | | | |
|-------------------------|-----|-----|-----|-------|-----|-----|-----|-----|
|                         | No. | Alaska Native Rate | US White Rate | Rate Ratio (P Value) | No. | Alaska Native Rate | US White Rate | Rate Ratio (P Value) |
| 70–79                   | 87  | 420.0             | 460.4         | 0.91 (.43)          |     |                  |               |                 |
| ≥80                     | 23  | 244.4             | 412.3         | 0.59 (.01)          |     |                  |               |                 |

Prostate

| Cancer Site/Age Group, y | Men | | | Women | | | | |
|-------------------------|-----|-----|-----|-------|-----|-----|-----|-----|
|                         | No. | Alaska Native Rate | US White Rate | Rate Ratio (P Value) | No. | Alaska Native Rate | US White Rate | Rate Ratio (P Value) |
| 30–39                   | 2   | 2.4              | 0.5           | 5.03 (.12)          |     |                  |               |                 |
| 40–49                   | 11  | 11.8             | 22.4          | 0.52 (.03)          |     |                  |               |                 |
| 50–59                   | 65  | 98.9             | 210.8         | 0.46 (.001)         |     |                  |               |                 |
| 60–69                   | 101 | 292.5            | 681.2         | 0.42 (.001)         |     |                  |               |                 |
| 70–79                   | 63  | 366.5            | 899.7         | 0.40 (.001)         |     |                  |               |                 |
| ≥80                     | 28  | 468.9            | 642.7         | 0.72 (.11)          |     |                  |               |                 |

Kidney

| Cancer Site/Age Group, y | Men | | | Women | | | | |
|-------------------------|-----|-----|-----|-------|-----|-----|-----|-----|
|                         | No. | Alaska Native Rate | US White Rate | Rate Ratio (P Value) | No. | Alaska Native Rate | US White Rate | Rate Ratio (P Value) |
| 30–39                   | 6   | 7.3              | 3.8           | 1.92 (.19)          | 4   | 4.7              | 2.6           | 1.78 (.38)         |
| 40–49                   | 13  | 14.3             | 13.6          | 1.05 (.93)          | 5   | 5.5              | 7.4           | 0.74 (.68)         |
| 50–59                   | 29  | 44.2             | 33.8          | 1.30 (.19)          | 24  | 35.7             | 16.6          | 2.14 (.001)        |
| 60–69                   | 30  | 87.5             | 68.4          | 1.27 (.22)          | 15  | 40.3             | 32.5          | 1.24 (.47)         |
| 70–79                   | 29  | 170.3            | 93.8          | 1.81 (.001)         | 14  | 65.8             | 46.2          | 1.42 (.25)         |
| ≥80                     | 7   | 108.9            | 91.2          | 1.19 (.75)          | 9   | 96.3             | 44.3          | 2.17 (.05)         |

*a Source of data: Surveillance Epidemiology and End Results (SEER) program SEER*Stat database (17).
Table 3. Joinpoint Analyses for Trends Among Alaska Native (1970–2011) and US White (1973–2011) 2-Year Averaged Annual Cancer Incidence Rates — Model Selections

| Site/Sex   | Trend 1  | APCa, b | Trend 2  | APCa, b | Trend 3  | APCa, b | Trend 4  | APCa, b |
|------------|----------|---------|----------|---------|----------|---------|----------|---------|
| All Sites  |          |         |          |         |          |         |          |         |
| Men and women |          |         |          |         |          |         |          |         |
| Alaska Native | 1970–2005 | 1.1b    | 2005–2011 | −0.9    |          |          |          |          |
| US white    | 1973–1982 | 0.9b    | 1982–1991 | 1.7b    | 1991–2008 | −0.3b   | 2008–2011 | 1.7b    |
| Men         |          |         |          |         |          |         |          |         |
| Alaska Native | 1970–2011 | 0.7b    |          |          |          |          |          |          |
| US white    | 1973–1989 | 1.5b    | 1989–1992 | 4.7b    | 1992–1995 | −3.7b   | 1995–2011 | −0.5b   |
| Women       |          |         |          |         |          |         |          |         |
| Alaska Native | 1970–2011 | 1.2b    |          |          |          |          |          |          |
| US white    | 1973–1982 | 0.5b    | 1982–1985 | 2.6b    | 1985–1999 | 0.5b    | 1999–2011 | −0.2b   |
| Lung        |          |         |          |         |          |         |          |         |
| Men and women |          |         |          |         |          |         |          |         |
| Alaska Native | 1970–1985 | 7.2b    | 1985–2011 | 0.2b    |          |          |          |          |
| US white    | 1973–1981 | 2.9b    | 1981–1990 | 1.3b    | 1990–2007 | −1.6b   | 2007–2011 | −2.6b   |
| Men         |          |         |          |         |          |         |          |         |
| Alaska Native | 1970–1995 | 2.8b    | 1995–2011 | −1.5b   |          |          |          |          |
| US white    | 1973–1978 | 2.6b    | 1978–1988 | 0.3b    | 1988–2007 | −1.6b   | 2007–2011 | −2.9b   |
| Women       |          |         |          |         |          |         |          |         |
| Alaska Native | 1970–1985 | 12.9b   | 1985–2011 | 0.9b    |          |          |          |          |
| US white    | 1973–1982 | 6.3b    | 1982–1991 | 3.5b    | 1991–2007 | 0.6b    | 2007–2011 | −2.5b   |
| Colorectal  |          |         |          |         |          |         |          |         |
| Men and women |          |         |          |         |          |         |          |         |
| Alaska Native | 1970–1999 | 1.6b    | 1999–2011 | −2.6b   |          |          |          |          |
| US white    | 1973–1985 | 0.9b    | 1985–1995 | −2.0b   | 1995–1998 | 2.1b    | 1998–2011 | −2.9b   |
| Men         |          |         |          |         |          |         |          |         |
| Alaska Native | 1970–1997 | 2.0b    | 1997–2011 | −1.9b   |          |          |          |          |
| US white    | 1973–1986 | 1.1b    | 1986–1995 | −2.3b   | 1995–1998 | 1.8b    | 1998–2011 | −3.3b   |
| Women       |          |         |          |         |          |         |          |         |
| Alaska Native | 1970–2005 | 0.9b    | 2005–2011 | −7.3b   |          |          |          |          |
| US white    | 1973–1984 | 0.7b    | 1984–1995 | −2.0b   | 1995–1998 | 2.4b    | 1998–2011 | −2.6b   |
| Breast      |          |         |          |         |          |         |          |         |
| Women       |          |         |          |         |          |         |          |         |
| Alaska Native | 1970–1997 | 5.1b    | 1997–2011 | −0.3b   |          |          |          |          |
| US white    | 1973–1980 | −0.5b   | 1980–1987 | 3.8b    | 1987–1999 | 0.5b    | 1999–2011 | −0.8b   |

a Alaska Native annual percentage change (APC) based on 2-year averaged incidence rates.
b APC significantly different from zero at α = .05.